Patent Application: Treating Blood Clots with Nerve Stimulation
Summary
The USPTO has published a patent application from ElectroCore, Inc. detailing systems and methods for treating blood clots using nerve stimulation, particularly for post-COVID conditions. The application describes transcutaneous electrical impulses to a vagus nerve branch to reduce antibodies associated with blood clotting.
What changed
This document is a published patent application (US20260088185A1) from ElectroCore, Inc. It describes a novel method for treating blood clots, specifically those associated with replicating pathogens like viruses (e.g., coronaviridae family), by applying transcutaneous electrical impulses to a cervical branch of the vagus nerve. The goal is to reduce antibodies linked to blood clotting, with a particular focus on treating post-COVID conditions.
As this is a patent application, it does not impose direct regulatory obligations on entities. However, it signals potential future developments in medical treatments for conditions like long COVID. Companies involved in medical devices, pharmaceuticals, or healthcare services, particularly those focused on neurological or infectious disease treatments, should be aware of this technological advancement for competitive intelligence and potential licensing opportunities.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SYSTEMS AND METHODS FOR TREATING BLOOD CLOTS WITH NERVE STIMULATION
Application US20260088185A1 Kind: A1 Mar 26, 2026
Assignee
ElectroCore, Inc.
Inventors
Joseph P. Errico, Bruce J. Simon, Peter Staats, Thomas Errico
Abstract
Systems and methods are provided for treating blood clots associated with a replicating pathogen, such as a virus in the coronaviridae family. The systems and methods include applying an electrical impulse transcutaneously through the outer skin surface of the patient to a cervical branch of the vagus nerve of the patient. The electrical impulse is sufficient to reduce a number of antibodies associated with blood clotting to reduce a level of blood clotting in the patient. The systems and methods are particularly useful for treating post-COVID conditions or post-acute sequelae of COVID-19 that develop in “long-haul” or COVID patients.
CPC Classifications
G16H 50/80 A61N 1/36 A61N 1/36034 A61N 1/36053 G16B 35/00 G16H 70/60
Filing Date
2025-11-29
Application No.
19403849
Related changes
Get daily alerts for USPTO Patent Applications - Health Informatics (G16H)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Health Informatics (G16H) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.